Company · Healthcare
Cancer research and treatment centre in Melbourne
Melbourne, VIC
Every investor coverage indicates participated in a round Peter MacCallum Cancer Centre raised.
Companies Peter MacCallum Cancer Centre acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Clare Slaney | Immunotherapy Scientist (former) | Brandon BioCatalyst, Main Sequence |
| Luc Furic | Scientist | Dealroom |
| Michael Hofman | Scientist | Dealroom |
| Mohammad Haskali | Scientist | Dealroom |
| Prof Sherene Loi | Group Leader | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming Peter MacCallum Cancer Centre. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne oncology startup Skopos Bio has raised a seed round from Tenmile, Tin Alley Ventures and Yosemite to advance radioactive cancer therapy toward human trials.
Profile of a Peter Mac spinout advancing solid-tumour cell therapies; recounts its Series A backers, later investment, grant support, and chief executive Sam Cobb's earlier career building and listing AdAlta.
Wholesale Investor's Steve Torso highlights Australian life sciences companies from the Emergence Preview Series, noting government grant funding, a Series A extension, venture co-investment, and a medtech company's ASX listing.
Also Wholesale Investor
Adelaide medtech Ferronova has banked another $6 million from returning backers to advance its surgical tracer for cancer, lifting Series A funding to $17.5 million; backer parent UltraGreen.ai floated in Singapore this month.
Also movefm.com.au
Adelaide biotech Ferronova added $6 million to its Series A from prior backers, lifting the round's total to $17.5 million; backer Renew's parent Ultragreen.ai floated in Singapore this month.
Also ferronova.com.au·movefm.com.au·Biotech Dispatch·Startup Daily
Main Sequence explains why it backed Currus Biologics, whose BEAT platform aims to make CAR-T cell therapies effective against solid tumours, starting with mesothelin-positive cancers, as the team prepares for a clinical trial.
University of Melbourne researchers describe a faster acoustic bioprinting method for human-like tissue; PhD candidate Callum Vidler's project recently won a $199,482 seed grant via the national AEA pilot program.
Profile of scientist-entrepreneur Andrew Wilks covering the GSK sale of his cancer molecule, his SYNthesis BioVentures fund's family-office backers, and portfolio plays including Aculeus Therapeutics.
Cancer biotech Amaroq Therapeutics appointed four experts to its advisory board as it moves toward clinical trials; the New Zealand company's backers include Brandon Capital, which reports $14m invested to date.
New Zealand biotech Amaroq Therapeutics reported early progress toward clinical trials and appointed four leading scientists to its scientific advisory board, strengthening its lncRNA cancer therapy programme.
Biotech Proacta's release: its Phase I cancer-drug trial is underway, and Alta Partners' new funding tops the Series A up to $12M alongside lead backer GBS Ventures; Alta's David Mack joins the board.